Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. [electronic resource]
Producer: 20140606Description: 183-188 p. digitalISSN:- 1776-260X
- Adult
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Bevacizumab
- Biomarkers, Tumor -- genetics
- Colorectal Neoplasms -- drug therapy
- GTP Phosphohydrolases -- genetics
- Humans
- Male
- Membrane Proteins -- genetics
- Middle Aged
- Mutation
- Treatment Outcome
No physical items for this record
Publication Type: Case Reports; Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.